Phase I Dose-Escalation Trial of CP-675,206 (Tremelimumab, Anti-CTLA-4 Monoclonal Antibody) for Patients With BCG-Resistant Localized Transitional Cell Carcinoma of the Bladder.

Trial Profile

Phase I Dose-Escalation Trial of CP-675,206 (Tremelimumab, Anti-CTLA-4 Monoclonal Antibody) for Patients With BCG-Resistant Localized Transitional Cell Carcinoma of the Bladder.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Oct 2015

At a glance

  • Drugs Tremelimumab (Primary) ; BCG
  • Indications Bladder cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 24 Mar 2011 Planned End Date changed from 1 May 2012 to 1 Jun 2012 as reported by ClinicalTrials.gov.
    • 06 Feb 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 06 Feb 2010 Actual initiation date (Jun 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top